Harbor Advisory Corp MA Has $6.41 Million Holdings in Thermo Fisher Scientific Inc. (NYSE:TMO)

Harbor Advisory Corp MA raised its stake in Thermo Fisher Scientific Inc. (NYSE:TMO) by 0.3% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 10,362 shares of the medical research company’s stock after acquiring an additional 30 shares during the quarter. Thermo Fisher Scientific makes up approximately 2.1% of Harbor Advisory Corp MA’s investment portfolio, making the stock its 19th largest position. Harbor Advisory Corp MA’s holdings in Thermo Fisher Scientific were worth $6,410,000 as of its most recent SEC filing.

A number of other hedge funds also recently made changes to their positions in TMO. Riverview Trust Co bought a new position in Thermo Fisher Scientific in the first quarter valued at about $81,000. Inspirion Wealth Advisors LLC bought a new position in Thermo Fisher Scientific in the 1st quarter valued at approximately $203,000. Sarasin & Partners LLP boosted its position in Thermo Fisher Scientific by 10.5% during the 1st quarter. Sarasin & Partners LLP now owns 459,793 shares of the medical research company’s stock worth $267,236,000 after buying an additional 43,678 shares during the period. First Financial Corp IN increased its position in Thermo Fisher Scientific by 1.4% in the 1st quarter. First Financial Corp IN now owns 2,136 shares of the medical research company’s stock valued at $1,241,000 after acquiring an additional 30 shares during the period. Finally, Prentice Wealth Management LLC raised its stake in shares of Thermo Fisher Scientific by 8.4% during the first quarter. Prentice Wealth Management LLC now owns 894 shares of the medical research company’s stock valued at $520,000 after acquiring an additional 69 shares during the last quarter. 89.23% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other news, CEO Marc N. Casper sold 10,000 shares of Thermo Fisher Scientific stock in a transaction on Wednesday, July 31st. The stock was sold at an average price of $617.21, for a total transaction of $6,172,100.00. Following the sale, the chief executive officer now directly owns 123,816 shares in the company, valued at $76,420,473.36. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. In related news, EVP Gianluca Pettiti sold 300 shares of the business’s stock in a transaction dated Friday, July 26th. The stock was sold at an average price of $600.85, for a total value of $180,255.00. Following the sale, the executive vice president now directly owns 17,887 shares in the company, valued at approximately $10,747,403.95. The trade was a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CEO Marc N. Casper sold 10,000 shares of the stock in a transaction dated Wednesday, July 31st. The stock was sold at an average price of $617.21, for a total transaction of $6,172,100.00. Following the transaction, the chief executive officer now owns 123,816 shares of the company’s stock, valued at $76,420,473.36. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 23,084 shares of company stock valued at $14,094,292 in the last 90 days. 0.34% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

TMO has been the subject of a number of recent research reports. Evercore ISI increased their price objective on Thermo Fisher Scientific from $605.00 to $630.00 and gave the company an “outperform” rating in a report on Tuesday, October 1st. Robert W. Baird raised their price objective on Thermo Fisher Scientific from $620.00 to $632.00 and gave the stock an “outperform” rating in a research report on Thursday, July 25th. Morgan Stanley upped their target price on Thermo Fisher Scientific from $655.00 to $680.00 and gave the company an “overweight” rating in a report on Friday, September 20th. Wells Fargo & Company assumed coverage on shares of Thermo Fisher Scientific in a research report on Tuesday, August 27th. They issued an “overweight” rating and a $670.00 price target on the stock. Finally, Barclays increased their price objective on shares of Thermo Fisher Scientific from $600.00 to $620.00 and gave the stock an “equal weight” rating in a research report on Tuesday, October 15th. Four analysts have rated the stock with a hold rating, eighteen have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, Thermo Fisher Scientific has an average rating of “Moderate Buy” and a consensus target price of $656.16.

Thermo Fisher Scientific Stock Down 1.2 %

Shares of NYSE TMO traded down $7.28 during mid-day trading on Tuesday, reaching $588.09. 427,628 shares of the company’s stock traded hands, compared to its average volume of 1,458,966. Thermo Fisher Scientific Inc. has a 1-year low of $415.60 and a 1-year high of $627.88. The stock has a market cap of $224.65 billion, a P/E ratio of 36.93, a PEG ratio of 3.85 and a beta of 0.77. The company has a debt-to-equity ratio of 0.64, a current ratio of 1.72 and a quick ratio of 1.37. The business has a 50-day simple moving average of $607.91 and a 200 day simple moving average of $584.40.

Thermo Fisher Scientific (NYSE:TMO) last announced its earnings results on Wednesday, July 24th. The medical research company reported $5.37 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.13 by $0.24. Thermo Fisher Scientific had a return on equity of 18.22% and a net margin of 14.69%. The company had revenue of $10.54 billion for the quarter, compared to analysts’ expectations of $10.50 billion. During the same quarter in the previous year, the firm earned $5.15 earnings per share. Thermo Fisher Scientific’s quarterly revenue was down 1.4% on a year-over-year basis. On average, analysts expect that Thermo Fisher Scientific Inc. will post 21.72 EPS for the current fiscal year.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.